# Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

> **NCT02004769** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 67 (actual)

## Conditions studied

- Stomach Neoplasms
- Neoplasms Metastasis
- ERBB2 Gene Amplification

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02004769
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02004769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02004769, "Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02004769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*